IKS Health announces generative AI platform built on Google cloud
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
Speakers for the Session are: Venkata Prasad K., Unit Head, Deepak Nitrite; Abhilash Pasham, Associate General Manager - Central Engineering & Projects, Dr. Reddy's Laboratories; C. V. Rajulu, Consultant, Industry; and Jyoti Shankar Jha, Senior Lead Scientist, Alleima India. The moderator for the Session is Pravin Prashant, Executive Editor, Indian Pharma Post
Speakers are: Ch. A. P. Rameswara Rao, National President, BDMAI; Dr. Paidi Yella Reddy, Founder, President & CEO, Sapala Organics; K. V. Rama Gopal, Site Manager & Executive Director, Clariant India; Dr. K. Nagaiah, Chief Scientist, CSIR - Indian Institute of Chemical Technology, Hyderabad; Dr. Satyanarayana Thirunahari, Senior General Manager - Process Safety & Engineering, Laurus Labs; and Yadavendra Shalgaonkar, Assistant General Manager - Tube Sales, Alleima India
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
Subscribe To Our Newsletter & Stay Updated